The Rheumatologist’s Role in COVID-19

REFERENCES

1. 1.↵
   1. Pan F,
   2. Ye T,
   3. Sun P,
   4. Gui S,
   5. Liang B,
   6. Li L,
   7. et al.

   Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia. Radiology 2020 Feb 13 (E-pub ahead of print).
2. 2.↵
   1. Lipsitch M,
   2. Swerdlow DL,
   3. Finelli L

   . Defining the Epidemiology of Covid-19 - studies needed. N Engl J Med 2020 Feb 19 (E-pub ahead of print).
3. 3.↵
   1. Wang D,
   2. Hu B,
   3. Hu C,
   4. Zhu F,
   5. Liu X,
   6. Zhang J,
   7. et al.

   Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020 Feb 7 (E-pub ahead of print).
4. 4.↵
   1. Chen N,
   2. Zhou M,
   3. Dong X,
   4. Qu J,
   5. Gong F,
   6. Han Y,
   7. et al.

   Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507–13.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Chen L,
   2. Liu HG,
   3. Liu W,
   4. Liu J,
   5. Liu K,
   6. Shang J,
   7. et al.

   Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. [Article in Chinese] Chin J Tuberc Respir Dis 2020 Feb 6 (E-pub ahead of print).
6. 6.↵
   1. Mehta P,
   2. McAuley DF,
   3. Brown M,
   4. Sanchez E,
   5. Tattersall RS,
   6. Manson JJ;
   7. HLH Across Speciality Collaboration, UK

   . COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020 Mar 16 (E-pub ahead of print).
7. 7.↵
   1. Eloseily EMA,
   2. Minoia F,
   3. Crayne CB,
   4. Beukelman T,
   5. Ravelli A,
   6. Cron RQ

   . Ferritin to erythrocyte sedimentation rate ratio: simple measure to identify macrophage activation syndrome in systemic juvenile idiopathic arthritis. ACR Open Rheumatol 2019;1:345–9.

   OpenUrl
8. 8.↵
   1. Fardet L,
   2. Galicier L,
   3. Lambotte O,
   4. Marzac C,
   5. Aumont C,
   6. Chahwan D,
   7. et al.

   Development and validation of a score for the diagnosis of reactive hemophagocytic syndrome (HScore). Arthritis Rheumatol 2014;66:2613–20.

   OpenUrlPubMed
9. 9.↵
   1. Henter JI,
   2. Horne A,
   3. Arico M,
   4. Egeler RM,
   5. Filipovich AH,
   6. Imashuku S,
   7. et al.

   HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48:124–31.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Allen CE,
    2. Yu X,
    3. Kozinetz CA,
    4. McClain KL

    . Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2008;50:1227–35.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Eloseily EM,
    2. Weiser P,
    3. Crayne CB,
    4. Haines H,
    5. Mannion ML,
    6. Stoll ML,
    7. et al.

    Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis. Arthritis Rheumatol 2020;72:326–34.

    OpenUrlPubMed
12. 12.↵
    1. Halyabar O,
    2. Chang MH,
    3. Schoettler ML,
    4. Schwartz MA,
    5. Baris EH,
    6. Benson LA,
    7. et al.

    Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome. Pediatr Rheumatol Online J 2019;17:7.

    OpenUrl
13. 13.↵
    1. Henderson LA,
    2. Cron RQ

    . Macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis in childhood inflammatory disorders: diagnosis and management. Paediatr Drugs 2020;22:29–44.

    OpenUrl
14. 14.↵
    1. US Food and Drug Administration

    . News release. [Internet. Accessed March 23, 2020.] Available from: www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-specifically-patients-rare-and-life-threatening-type-immune-disease
15. 15.↵
    1. Shakoory B,
    2. Carcillo JA,
    3. Chatham WW,
    4. Amdur RL,
    5. Zhao H,
    6. Dinarello CA,
    7. et al.

    Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med 2016;44:275–81.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Maude SL,
    2. Frey N,
    3. Shaw PA,
    4. Aplenc R,
    5. Barrett DM,
    6. Bunin NJ,
    7. et al.

    Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014;371:1507–17.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Liu A

    . China turns Roche arthritis drug Actemra against COVID-19 in new treatment guidelines. [Internet. Accessed March 23, 2020.] Available from: www.fiercepharma.com/pharma-asia/china-turns-roche-arthritis-drug-actemra-against-covid-19-new-treatment-guidelines
18. 18.↵
    1. Albeituni S,
    2. Verbist KC,
    3. Tedrick PE,
    4. Tillman H,
    5. Picarsic J,
    6. Bassett R,
    7. et al.

    Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis. Blood 2019;134:147–59.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. Crayne CB,
    2. Albeituni S,
    3. Nichols KE,
    4. Cron RQ

    . The immunology of macrophage activation syndrome. Front Immunol 2019;10:119.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Schulert GS,
    2. Zhang M,
    3. Fall N,
    4. Husami A,
    5. Kissell D,
    6. Hanosh A,
    7. et al.

    Whole-exome sequencing reveals mutations in genes linked to hemophagocytic lymphohistiocytosis and macrophage activation syndrome in fatal cases of H1N1 influenza. J Infect Dis 2016;213:1180–8.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Harms PW,
    2. Schmidt LA,
    3. Smith LB,
    4. Newton DW,
    5. Pletneva MA,
    6. Walters LL,
    7. et al.

    Autopsy findings in eight patients with fatal H1N1 influenza. Am J Clin Pathol 2010;134:27–35.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Crayne C,
    2. Cron RQ

    . Pediatric macrophage activation syndrome, recognizing the tip of the iceberg. Eur J Rheumatol 2019;7 Suppl 1:1–8.

    OpenUrl
23. 23.↵
    1. Cron RQ,
    2. Behrens EM,
    3. Shakoory B,
    4. Ramanan AV,
    5. Chatham WW

    . Does viral hemorrhagic fever represent reactive hemophagocytic syndrome? J Rheumatol 2015;42:1078–80.

    OpenUrlFREE Full Text
24. 24.
    1. Huang C,
    2. Wang Y,
    3. Li X,
    4. Ren L,
    5. Zhao J,
    6. Hu Y,
    7. et al.

    Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.

    OpenUrlCrossRefPubMed
25. 25.
    1. Shi H,
    2. Han X,
    3. Jiang N,
    4. Cao Y,
    5. Alwalid O,
    6. Gu J,
    7. et al.

    Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis 2020 Feb 24 (E-pub ahead of print).
26. 26.
    1. Canna SW,
    2. Girard C,
    3. Malle L,
    4. de Jesus A,
    5. Romberg N,
    6. Kelsen J,
    7. et al.

    Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition. J Allergy Clin Immunol 2017;139:1698–701.

    OpenUrlCrossRefPubMed
27. 27.
    1. Lounder DT,
    2. Bin Q,
    3. de Min C,
    4. Jordan MB

    . Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections. Blood Adv 2019;3:47–50.

    OpenUrlAbstract/FREE Full Text
28. 28.
    1. Goldsmith SR,
    2. Saif Ur Rehman S,
    3. Shirai CL,
    4. Vij K,
    5. DiPersio JF

    . Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib. Blood Adv 2019;3:4131–5.

    OpenUrl
29. 29.
    1. Henzan T,
    2. Nagafuji K,
    3. Tsukamoto H,
    4. Miyamoto T,
    5. Gondo H,
    6. Imashuku S,
    7. et al.

    Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis. Am J Hematol 2006;81:59–61.

    OpenUrlCrossRefPubMed